95 related articles for article (PubMed ID: 2159428)
1. Clinical aspects of ovarian tumors of low malignant potential.
Dgani R; Blickstein I; Shoham Z; Czernobilsky B; Ben-Hur H; Shani A; Katz Z; Borenstein R
Eur J Obstet Gynecol Reprod Biol; 1990; 35(2-3):251-8. PubMed ID: 2159428
[TBL] [Abstract][Full Text] [Related]
2. Epithelial ovarian carcinoma of low malignant potential.
Barnhill D; Heller P; Brzozowski P; Advani H; Gallup D; Park R
Obstet Gynecol; 1985 Jan; 65(1):53-9. PubMed ID: 2981419
[TBL] [Abstract][Full Text] [Related]
3. Ovarian epithelial tumors of low malignant potential.
Chien RT; Rettenmaier MA; Micha JP; DiSaia PJ
Surg Gynecol Obstet; 1989 Aug; 169(2):143-6. PubMed ID: 2756462
[TBL] [Abstract][Full Text] [Related]
4. Long term survival outcomes of stage I mucinous ovarian cancer - A clinical calculator predictive of chemotherapy benefit.
Richardson MT; Mysona DP; Klein DA; Mann A; Liao CI; Diver EJ; Darcy KM; Tian C; She JX; Ghamande S; Van Le L; Kapp DS; Chan JK
Gynecol Oncol; 2020 Oct; 159(1):118-128. PubMed ID: 32828578
[TBL] [Abstract][Full Text] [Related]
5. Ovarian carcinoma of low malignant potential: staging and treatment.
Nation JG; Krepart GV
Am J Obstet Gynecol; 1986 Feb; 154(2):290-3. PubMed ID: 3004219
[TBL] [Abstract][Full Text] [Related]
6. [An analysis of factors influential in improving the survival rate of patients with ovarian cancer].
Ohta M; Tomoda Y; Kano T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1008-15. PubMed ID: 2730004
[TBL] [Abstract][Full Text] [Related]
7. [Importance of clinically prognostic factors in the treatment of advanced ovarian carcinoma].
Albrecht M; Goepel E; Simon WE; Trams G
Geburtshilfe Frauenheilkd; 1985 Jul; 45(7):482-7. PubMed ID: 2993094
[TBL] [Abstract][Full Text] [Related]
8. Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience.
Nassar HR; Zeeneldin AA; Helal AM; Ismail YM; Elsayed AM; Elbassuiony MA; Moneer MM
Asian Pac J Cancer Prev; 2015; 16(16):7237-42. PubMed ID: 26514517
[TBL] [Abstract][Full Text] [Related]
9. [Clinical studies on malignant ovarian tumor--with special reference to therapy and prognosis of epithelial ovarian tumor].
Iwasawa H; Sekiya S; Kaihou T; Takamizawa H
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Apr; 36(4):525-30. PubMed ID: 6325559
[TBL] [Abstract][Full Text] [Related]
10. [Effects of chemo-immunotherapy of malignant ovarian tumors. Collaborated study with affiliated hospitals].
Ota M
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Aug; 37(8):1391-9. PubMed ID: 2995514
[No Abstract] [Full Text] [Related]
11. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study.
Young RC; Brady MF; Nieberg RK; Long HJ; Mayer AR; Lentz SS; Hurteau J; Alberts DS
J Clin Oncol; 2003 Dec; 21(23):4350-5. PubMed ID: 14645424
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
13. Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?
Kajiyama H; Mizuno M; Shibata K; Umezu T; Suzuki S; Yamamoto E; Mitsui H; Sekiya R; Niimi K; Kawai M; Nagasaka T; Kikkawa F
Eur J Obstet Gynecol Reprod Biol; 2014 Oct; 181():305-10. PubMed ID: 25203309
[TBL] [Abstract][Full Text] [Related]
14. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study.
Bertelsen K
Gynecol Oncol; 1990 Aug; 38(2):203-9. PubMed ID: 2167280
[TBL] [Abstract][Full Text] [Related]
15. Survival impact of capsule status in stage I ovarian mucinous carcinoma-A mulicentric retrospective study.
Kajiyama H; Suzuki S; Yoshikawa N; Kawai M; Nagasaka T; Kikkawa F
Eur J Obstet Gynecol Reprod Biol; 2019 Mar; 234():131-136. PubMed ID: 30685661
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
Ansaloni L; Agnoletti V; Amadori A; Catena F; Cavaliere D; Coccolini F; De Iaco P; Di Battista M; Framarini M; Gazzotti F; Ghermandi C; Kopf B; Saponara M; Tauceri F; Vallicelli C; Verdecchia GM; Pinna AD
Int J Gynecol Cancer; 2012 Jun; 22(5):778-85. PubMed ID: 22572845
[TBL] [Abstract][Full Text] [Related]
17. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
[TBL] [Abstract][Full Text] [Related]
18. A clinical appraisal of stage 1 mucinous carcinoma of the ovary.
Soeters R; Levin W; Tiltman A; Bloch B; Dehaeck CM
Gynecol Oncol; 1989 May; 33(2):222-4. PubMed ID: 2539318
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.
Gadducci A; Cosio S; Zola P; Sostegni B; Fuso L; Sartori E
Int J Gynecol Cancer; 2013 Mar; 23(3):461-8. PubMed ID: 23370604
[TBL] [Abstract][Full Text] [Related]
20. Malignant and borderline epithelial ovarian tumors in the pediatric and adolescent population.
Nasioudis D; Alevizakos M; Holcomb K; Witkin SS
Maturitas; 2017 Feb; 96():45-50. PubMed ID: 28041594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
